TENUMOMERAN
UNII 2CJX8CX5ZF

Substance Identification & Data

This profile provides standardized clinical and technical data for Tenumomeran, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 2CJX8CX5ZF.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3024099-60-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

2CJX8CX5ZF

CAS Registry Number

3024099-60-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TENUMOMERAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C224795

National Cancer Institute reference terminology for clinical and research data.

INN ID

13618

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-162

Identifier assigned by the United States Adopted Names Council.

Substance Type

Tenumomeran

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tenumomeran. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Tenumomeran

Common Names & Synonyms

RBL015.2

RNA (recombinant 5′-[1,2-[m7Gm-(5′→5′)-p-[P(R)]-sp-p-G]]-capped human major histocompatibility complex class I α chain secretory signal peptide plus codon-optimized human papillomavirus 16 E6 protein transgene plus tetanus toxoid T helper epitope P2P16 plus human major histocompatibility complex class I trafficking and cytoplasmic domain-specifying plus 5′- and 3′-untranslated flanking region-containing poly(A)-tailed messenger RBL015.2), inner salt

TENUMOMERAN [USAN]

messenger RNA (mRNA), 5' capped (with an anti-reverse cap analogue [ARCA] [m<sub>2</sub><sup>7,2'-O</sup> G+5'ppsp5'G]), encoding codon-optimised human papilloma virus 16 (HPV16) early protein 6 (E6) tumour-associated antigen, preceded by a secretory signal peptide sequence derived from the human major histocompatibility complex (MCH) class I alpha chain, and followed by sequences coding for tetanus toxoid-derived T helper epitopes (P2P16) and a major histocompatibility complex (MHC) class I trafficking domain [MITD], each of them separated by glycine/serine rich linkers. The transgene is flanked by 5' and 3' untranslated regions (UTR) followed by a 3' polyadenylation (polyA) tail. The 5' UTR is derived from human alpha-globin gene and contains an optimised Kozak sequence; the synthetic 3' UTR is a combination of two elements derived from the amino-terminal enhancer of split (AES) mRNA and mitochondrial encoded 12S ribosomal RNA. The polyA tail consists of 30 adenosine residues followed by a 10-nucleotide linker sequence and another 70 adenosine residues

tenumomeran [INN]

Technical Codes

BNT113 HPV E6

External Clinical & Regulatory Resources

Previous UNII2CJM9X7KEU

Next UNII2CKG6TX32F